-+ 0.00%
-+ 0.00%
-+ 0.00%

Veru enters clinical supply deal with Novo Nordisk for enobosarm-Wegovy obesity trial

PUBT·06/04/2026 12:33:26
Listen to the news
Veru enters clinical supply deal with Novo Nordisk for enobosarm-Wegovy obesity trial
  • Veru entered a clinical supply agreement with Novo Nordisk on June 2, 2026 to support its Phase 2b PLATEAU obesity study.
  • Novo Nordisk will provide Wegovy at no charge for use in the trial combining Wegovy with enobosarm in older adults.
  • Veru will sponsor and run the study, providing Novo Nordisk trial-design and clinical-conduct insights, including protocol and safety updates.
  • The deal grants Novo Nordisk a right of first negotiation on any future enobosarm combination with its GLP-1 products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-019478), on June 04, 2026, and is solely responsible for the information contained therein.